Restasis Ruling Could Be Bad Sign For Tribal Patent Pacts
Allergan suffered a major setback when a federal judge invalidated parts of four patents for the dry-eye drug Restasis, but the judge's concerns about striking a deal with a Native American...To view the full article, register now.
Already a subscriber? Click here to view full article